コンテンツへスキップ
Merck

SML2499

Sigma-Aldrich

TY-52156

≥98% (HPLC)

別名:

1-(4-Chlorophenylamino)-1-(4-chlorophenylhydrazono)-3,3-dimethyl-2-butanone, 1-(4-Chlorophenylhydrazono)-1-(4-chlorophenylamino)-3,3-dimethyl-2-butanone, N-(4-Chloroanilino)-N′-(4-chlorophenyl)-3,3-dimethyl-2-oxobutanimidamide, TY 52156, TY52156

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C18H19Cl2N3O
CAS番号:
分子量:
364.27
UNSPSCコード:
12352200
NACRES:
NA.77

アッセイ

≥98% (HPLC)

形状

powder

white to very dark brown

溶解性

DMSO: 2 mg/mL, clear

保管温度

2-8°C

SMILES記法

CC(C)(C(/C(NC1=CC=C(C=C1)Cl)=N/NC2=CC=C(C=C2)Cl)=O)C

InChI

1S/C18H19Cl2N3O/c1-18(2,3)16(24)17(21-14-8-4-12(19)5-9-14)23-22-15-10-6-13(20)7-11-15/h4-11,22H,1-3H3,(H,21,23)

InChI Key

XONRRGIRSGNWFP-UHFFFAOYSA-N

生物化学的/生理学的作用

TY-52156 is a potent sphingosine 1-phosphate (S1P) receptor 3 (S1P3; S1PR3) antagonist that selectively inhibits S1P-stimulated Ca2+ response in human S1P3-expressing cells (Ki = 110 nM) and Eu-GTP binding to S1P3-containing membranes over those of S1P1/2/4/5. TY-52156 inhibits S1P3-dependent signaling events in human coronary artery smooth muscle cells (1 μM), S1P3-dependent coronary flow decrease in perfused rat hearts, as well as S1P3-mediated acute mechanical pain in mice (10 nmol/20 μL/paw id.) and bradycardia in anesthetized rats (30 mg/kg TY-52156 p.o.) in vivo with good oral bioavailability (F = 70.9%; 1 mg/kg p.o. in rats).

保管分類コード

11 - Combustible Solids

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

SML2499-VAR:
SML2499-BULK:
SML2499-5MG:
SML2499-25MG:


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Zhijing Zhao et al.
Experimental and therapeutic medicine, 15(6), 5007-5016 (2018-05-29)
Thyroid carcinoma is characterized by an aggressive behavior, lack of effective targeted therapies and a high rate of relapse. Sphingosine kinase 1 (SPHK1) has been reported to be a critical regulatory factor in the progression of thyroid carcinoma, but the
Xiao-Jing Sun et al.
Journal of cellular and molecular medicine, 22(3), 1769-1777 (2017-11-24)
Cumulating evidences suggested an important role of sphingosine-1-phosphate (S1P) and its receptors in regulating endothelial barrier integrity. Our previous study revealed that the circulating S1P levels and renal expression of S1PRs correlated with disease activity and renal damage in patients
Iuliia Filipenko et al.
Biochimica et biophysica acta, 1861(11), 1840-1851 (2016-09-13)
Breast cancer is one of the most common and devastating malignancies among women worldwide. Recent evidence suggests that malignant progression is also driven by processes involving the sphingolipid molecule sphingosine 1-phosphate (S1P) and its binding to cognate receptor subtypes on
Akira Murakami et al.
Molecular pharmacology, 77(4), 704-713 (2010-01-26)
Sphingosine 1-phosphate (S1P) induces diverse biological responses in various tissues by activating specific G protein-coupled receptors (S1P(1)-S1P(5) receptors). The biological signaling regulated by S1P(3) receptor has not been fully elucidated because of the lack of an S1P(3) receptor-specific antagonist or
Luca Piali et al.
Pharmacology research & perspectives, 5(6) (2017-12-12)
Sphingosine-1-phosphate receptor 1 (S1P1 ) modulators sequester circulating lymphocytes within lymph nodes, thereby preventing potentially pathogenic autoimmune cells from exiting into the blood stream and reaching inflamed tissues. S1P1 receptor modulation may thus offer potential to treat various autoimmune diseases.

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)